Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
PR Newswire•03/08/2026•07:45 ET
0
Whiz Insights
Get started
Create a free account to read the full story.